Glanzmann Thrombasthenia
A rare inherited platelet function disorder caused by mutations in the ITGA2B or ITGB3 genes, impairing platelet aggregation and leading to mucocutaneous bleeding.
- Autosomal Recessive Inheritance
- Platelet Aggregation Defect
- Specialist Hematology Care
- Estimated Prevalence
- ~1 in 1,000,000
- Inheritance Pattern
- Autosomal Recessive
- Genes Involved
- ITGA2B, ITGB3
- Care Access
- Specialist Hematology & Platelet Transfusion Support
Condition Overview
Glanzmann thrombasthenia is a rare inherited platelet function disorder caused by mutations in the ITGA2B or ITGB3 genes, which together encode the glycoprotein IIb/IIIa receptor on the platelet surface. This receptor is essential for platelets to bind fibrinogen and aggregate, the key step that forms a platelet plug at sites of vessel injury.
Unlike disorders of the clotting factor cascade, Glanzmann thrombasthenia is a primary platelet function defect: platelet counts are typically normal, but the platelets themselves cannot aggregate properly, leading to mucocutaneous bleeding that can range from mild bruising to severe hemorrhage.
The condition is inherited in an autosomal recessive pattern and is more frequently reported in populations with higher rates of consanguineous marriage. Severity is graded by the degree of receptor deficiency, though bleeding tendency can vary even among individuals with similar receptor levels.
Types and Variants
Glanzmann thrombasthenia is classified by the degree of glycoprotein IIb/IIIa receptor deficiency on the platelet surface.
Symptoms and Signs
Bleeding in Glanzmann thrombasthenia is predominantly mucocutaneous, reflecting the role of platelets in maintaining the integrity of small blood vessels.
Causes and Risk Factors
Glanzmann thrombasthenia results from inherited mutations affecting the structure or expression of the platelet glycoprotein IIb/IIIa receptor.
Diagnosis and Investigations
Because platelet counts are typically normal, diagnosis of Glanzmann thrombasthenia relies on specialized platelet function and receptor testing.
Severity Classification
Glanzmann thrombasthenia is classified by glycoprotein IIb/IIIa receptor expression level rather than staged like cancer, which helps guide expected bleeding risk.
Standard Treatment Options
Management of Glanzmann thrombasthenia focuses on controlling acute bleeding episodes and minimizing bleeding risk around procedures, since there is no way to permanently correct the underlying platelet defect.
Advanced and Emerging Therapies
Research continues into therapies that reduce reliance on platelet transfusion and address the underlying platelet defect.
Recombinant Factor Therapy
Recombinant Activated Factor VII (rFVIIa)
An established option for managing bleeding episodes and surgical prophylaxis without relying on platelet transfusion.
Gene Therapy Research
Investigational Gene Correction Approaches
Early-stage research exploring gene-based correction of ITGA2B/ITGB3 mutations.
Stem Cell Transplant Research
Hematopoietic Stem Cell Transplantation
Has been explored in select severe cases as a potential curative approach, though it carries significant transplant-related risks and is not standard practice.
Specialist Hematology Access
Cross-Border Specialist Coordination
Access to comprehensive bleeding disorder centers experienced in managing rare platelet function disorders.
Biomarkers and Laboratory Monitoring
Specific platelet function and receptor markers, rather than standard clotting factor tests, are central to diagnosing and monitoring this condition.
When a Second Opinion May Be Important
Given the rarity of Glanzmann thrombasthenia, specialist input is valuable at several stages of care.
Clinical Trials and Research
Prognosis and Outlook
With appropriate diagnosis and a structured bleeding management plan, most individuals with Glanzmann thrombasthenia can lead active lives, though lifelong specialist follow-up remains important.
Supportive Care and Living With Glanzmann Thrombasthenia
Day-to-day management focuses on minimizing bleeding triggers and ensuring rapid access to appropriate treatment when bleeding occurs.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with Glanzmann thrombasthenia access specialist hematology review, coordinate second opinions on complex bleeding management plans, and connect with comprehensive bleeding disorder treatment centers internationally.
Get a free case reviewFrequently Asked Questions
Glanzmann thrombasthenia is a rare inherited platelet function disorder caused by mutations affecting the glycoprotein IIb/IIIa receptor, which platelets need to aggregate and form a clot.
No. Platelet counts are typically normal; the defect lies in the platelets' ability to function and stick together, not in their number.
It follows an autosomal recessive pattern, requiring mutations in both copies of the ITGA2B or ITGB3 gene for symptoms to appear.
Easy bruising, frequent nosebleeds, and bleeding gums from early childhood are common early signs that prompt evaluation.
Diagnosis relies on specialized platelet aggregation studies and flow cytometry testing for glycoprotein IIb/IIIa receptor levels, since standard blood counts are usually normal.
Platelet transfusions can be effective but carry a risk of antibody development with repeated use, so they are often reserved for severe bleeding not responding to other measures.
There is no routine cure, though stem cell transplantation has been explored in select severe cases; most patients are managed with bleeding prevention strategies and targeted treatment of episodes.
Yes, with coordinated care between hematology and obstetrics to plan for bleeding risk during delivery and the postpartum period.
Genetic counseling and testing of close relatives can identify carriers or other affected individuals, particularly in families with known mutations.
Yes. CancerFax helps patients with Glanzmann thrombasthenia get their medical reports reviewed by specialists, coordinate second opinions, and connect with comprehensive bleeding disorder centers and advanced therapy access internationally.
Get Expert Guidance for Glanzmann Thrombasthenia
Send your medical reports for specialist hematology review and explore coordinated care options.